Treating Atopic Dermatitis: Moving from Symptoms to Underlying Pathology – Expert Panel Discussion
This activity has been designed to meet the educational needs of dermatologists, allergists, immunology specialists, internists and primary care providers including physicians, nurse practitioners, physician assistants and other healthcare providers responsible for the diagnosis, treatment, or management of patients with atopic dermatitis. No prerequisites required.
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease, associated with a heterogeneous presentation and clinical course. Management of patients with AD requires a thorough and multifaceted approach that includes not only lifestyle and nonpharmacologic interventions, but also topical and systemic treatments: Topical therapy for patients with mild-to-moderate AD and oral agents for patients with moderate-to severe AD. In adults, biologic therapy is now available for more severe presentations of the disease. Yet, many questions remain regarding not only the appropriate use of these interventions in patients with different levels of severity but also the way in which severity is assessed. There is no standard definition of AD severity. Rather, AD severity encompasses the converging effects of the intensity and extent of lesions, chronicity and flares, intensity of itch, pain, sleep disturbance, mental health symptoms, and impact on activities of daily living.
This interactive video activity features a panel discussion among 3 AD experts covering a wide range of topics, from highlights of the latest study results of AD therapies presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting and the 42nd Hawaii Dermatology Seminar, as well as other “hot-button issues” that clinicians face in clinical practice managing AD patients (eg, use of antihistamines, bleach baths, etc).
The goal of this activity is to give healthcare providers who are responsible for the diagnosis, treatment, or management of patients with AD a greater confidence in appropriately using newer AD therapies and ways to successfully implement other strategies (both pharmacologic and nonpharmacologic) into the management of their patients with AD, to increase treatment success, and improve their patients’ quality of life.
Upon completion of this activity, participants will be better able to do the following:
- RECOGNIZE the latest science on the pathogenesis and related treatment implications of AD.
- Evaluate the most recent efficacy and safety data on newly approved and investigational treatment options for AD.
- Assess the clinical practice implications of newly acquired information on the development of treatment paradigms for AD.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Jonathan I. Silverberg, MD, PhD, MPH||
Consultant/Advisor: AbbVie Inc, Eli Lilly and Company, Galderma Medical Solutions, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, IntraDerm Pharmaceuticals, Kiniksa Pharmaceuticals, LEO Pharma Inc, Menlo Therapeutics, Pfizer Inc, Realm Therapeutics Inc, Regeneron-Sanofi, and Roivant Sciences Ltd.
Grant/Research Support: GlaxoSmithKline plc.
Speakers’ Bureau: Regeneron-Sanofi.
|Elaine C. Siegfried, MD||
Consultant/Advisor: Dermavant Sciences Inc, Ely Lilly and Company, GlaxoSmithKline plc, LEO Pharma Inc, Pierre Fabre, and Regeneron.
Speakers’ Bureau: Pfizer Inc.
|Linda Stein-Gold, MD||
Consultant/Advisor: LEO Pharma Inc, Medimetrix Group Inc, Pfizer Inc, and Sanofi-Regeneron.
Research Grant: LEO Pharma Inc, Pfizer Inc, and Valeant Pharmaceuticals International Inc.
Speakers’ Bureau: LEO Pharma Inc, Pfizer Inc, Sanofi-Regeneron, and Valeant Pharmaceuticals International Inc; Spouse: Valeant Pharmaceuticals International Inc.
Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Daniel Guinee; Mary Gabb, MS; and, Lisa Mangione hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education ASiM CE LLC.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM CE LLC, The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM CE LLC, and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: August 8, 2018
Expiration date: August 7, 2019